Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

Novo Nordisk CEO Mike Doustdar faces pressure to outline a strategy for competing with Eli Lilly in the U.S. weight-loss drug market and reducing the company's reliance on blockbuster Wegovy. Investors will focus on plans to sustain growth beyond Wegovy, with the leadership response potentially influencing Novo Nordisk's near-term valuation outlook.